Evidence map›Paper›PMID 29330321›Full record

ArticleJournal of immunology (Baltimore, Md. : 1950)2018

Osteopontin Promotes Protective Antigenic Tolerance against Experimental Allergic Airway Disease.

Themis Alissafi, Evangelia Kourepini, Davina C M Simoes, Nikolaos Paschalidis, Maria Aggelakopoulou, Tim Sparwasser, Louis Boon, Hamida Hammad, Bart N Lambrecht, Vily Panoutsakopoulou

Open access · bronzeAbstract read
In one paragraph

Article in Journal of immunology (Baltimore, Md. : 1950), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.8field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 13 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Review
  6. Review
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 4 countries.

Themis AlissafiCellular Immunology Laboratory, Center for Basic Research, Biomedical Research Foundation of the Academy of Athens, 11527 Athens, Greece.ORCID 0000-0002-4002-6008
Evangelia KourepiniCellular Immunology Laboratory, Center for Basic Research, Biomedical Research Foundation of the Academy of Athens, 11527 Athens, Greece.ORCID 0000-0002-2299-1007
Davina C M SimoesCellular Immunology Laboratory, Center for Basic Research, Biomedical Research Foundation of the Academy of Athens, 11527 Athens, Greece.
Nikolaos PaschalidisCellular Immunology Laboratory, Center for Basic Research, Biomedical Research Foundation of the Academy of Athens, 11527 Athens, Greece.ORCID 0000-0001-6278-4144
Maria AggelakopoulouCellular Immunology Laboratory, Center for Basic Research, Biomedical Research Foundation of the Academy of Athens, 11527 Athens, Greece.
Tim SparwasserInstitute of Infection Immunology, TWINCORE, Centre for Experimental and Clinical Infection Research, 30625 Hannover, Germany, a Joint Venture between the Helmholtz Centre for Infection Research, 38124 Braunschweig, Germany and the Hannover Medical School, 30625 Hannover, Germany; and.
Louis BoonBioceros BV, 3584 CM Utrecht, the Netherlands.
Hamida HammadVIB Center for Inflammation Research, Ghent University, 9052 Ghent, Belgium.
Bart N LambrechtVIB Center for Inflammation Research, Ghent University, 9052 Ghent, Belgium.
Vily PanoutsakopoulouCellular Immunology Laboratory, Center for Basic Research, Biomedical Research Foundation of the Academy of Athens, 11527 Athens, Greece; vpan@bioacademy.gr.ORCID 0000-0002-1569-1508
Academy of Athens · GRGhent University · BEMedizinische Hochschule Hannover · DEPolpharma Biologics (Netherlands) · NL

Funding

European Research Council 243322European Research Council 789384
6 · The paper itself

Abstract

In the context of inflammation, osteopontin (Opn) is known to promote effector responses, facilitating a proinflammatory environment; however, its role during antigenic tolerance induction is unknown. Using a mouse model of asthma, we investigated the role of Opn during antigenic tolerance induction and its effects on associated regulatory cellular populations prior to disease initiation. Our experiments demonstrate that Opn drives protective antigenic tolerance by inducing accumulation of IFN-β-producing plasmacytoid dendritic cells, as well as regulatory T cells, in mediastinal lymph nodes. We also show that, in the absence of TLR triggers, recombinant Opn, and particularly its SLAYGLR motif, directly induces IFN-β expression in Ag-primed plasmacytoid dendritic cells, which renders them extra protective against induction of allergic airway disease upon transfer into recipient mice. Lastly, we show that blockade of type I IFNR prevents antigenic tolerance induction against experimental allergic asthma. Overall, we unveil a new role for Opn in setting up a tolerogenic milieu boosting antigenic tolerance induction, thus leading to prevention of allergic airway inflammation. Our results provide insight for the future design of immunotherapies against allergic asthma.

Indexed as

AnimalsDendritic CellsImmune ToleranceInterferon-betaMiceMice, TransgenicOsteopontinRespiratory HypersensitivityT-Lymphocytes, RegulatoryInterferon-betaOsteopontinSpp1 protein, mouse

Identifiers

PMID29330321
PMCPMC7610813
OpenAlexW2783690605

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.